A Medicinal Chemistry Perspective on Developing Inhaled Drugs for Respiratory Diseases

Zbigniew Bartuzi^*
*Correspondence: Zbigniew Bartuzi, Department of Infectious Diseases and Hepatology, Nicolaus Copernicus University in Toruń, 85-030 Bydgoszcz, Poland, Email:

Introduction

Applied medicinal chemistry is the application of chemical principles and techniques to the discovery and development of new drugs for the treatment of diseases. Medicinal chemistry plays a vital role in the development of drugs by designing and synthesizing molecules that can selectively target specific biological targets, such as proteins, enzymes, and receptors. Medicinal chemists work collaboratively with biologists, pharmacologists, and other researchers to design and optimize drug molecules that have the desired pharmacological properties, such as potency, selectivity, and safety.

The process of drug discovery and development involves several stages, including target identification, lead identification, lead optimization, preclinical testing, clinical trials, and regulatory approval. Medicinal chemists play a critical role in the early stages of drug discovery by identifying and designing molecules that can interact with biological targets. The identification of a lead compound is the first step in drug discovery, and medicinal chemists use various techniques to identify compounds that have the desired biological activity, such as high potency and selectivity. Once a lead compound has been identified, medicinal chemists work to optimize its pharmacological properties by modifying its chemical structure to improve its efficacy and reduce toxicity [1].

Description

One of the essential tools of medicinal chemistry is computer-aided drug design (CADD), which uses computational methods to predict the binding of drug molecules to biological targets. CADD allows medicinal chemists to design and optimize drug molecules with the desired pharmacological properties and to reduce the time and cost of drug discovery. CADD involves several techniques, including molecular docking, molecular dynamics simulations, and virtual screening. These methods allow medicinal chemists to design and test thousands of drug molecules in silico, reducing the need for expensive and timeconsuming laboratory experiments [2].

Another critical aspect of medicinal chemistry is the understanding of the structure-activity relationship (SAR), which refers to the relationship between the chemical structure of a drug molecule and its pharmacological activity. Medicinal chemists use SAR to optimize the pharmacological properties of drug molecules by modifying their chemical structure. By understanding the SAR of a drug molecule, medicinal chemists can predict the pharmacological activity of related compounds and optimize their chemical structure to improve their potency and selectivity. Medicinal chemistry also plays a crucial role in drug metabolism and pharmacokinetics (DMPK), which involves the study of how drugs are metabolized and eliminated from the body. DMPK studies are essential in predicting the safety and efficacy of drug molecules in humans. Medicinal chemists use DMPK data to optimize the pharmacological properties of drug molecules, such as their bioavailability and half-life.

The development of new drugs is a complex and challenging process that requires collaboration between several disciplines, including medicinal chemistry, biology, pharmacology, and clinical research. Medicinal chemists work collaboratively with biologists and pharmacologists to identify and optimize drug molecules that have the desired pharmacological properties. Medicinal chemists also work closely with clinical researchers to develop safe and effective drug formulations and to conduct clinical trials to evaluate the safety and efficacy of new drugs [3].

Medicinal chemistry has played a significant role in the development of several essential drugs, such as antibiotics, anticancer agents, and cardiovascular drugs. The discovery and development of new drugs are essential in improving the treatment of diseases and reducing the burden of illness. The field of medicinal chemistry continues to evolve, with new techniques and approaches being developed to improve the efficiency and effectiveness of drug discovery and development. Computational methods are often used to predict the binding affinity and selectivity of a compound to the target protein. These methods include molecular docking, molecular dynamics simulations, and quantitative structureactivity relationship (QSAR) models. Molecular docking is a computational technique that predicts the binding mode of a ligand to a protein target based on its shape, electrostatics, and other properties. Molecular dynamics simulations are used to study the dynamic behavior of a ligand-protein complex over time. QSAR models use statistical methods to correlate the chemical structure of a compound with its biological activity.

Experimental methods are used to validate the computational predictions and to optimize the chemical properties of the compounds. These methods include chemical synthesis, high-throughput screening, and medicinal chemistry optimization. Chemical synthesis involves the preparation of compounds using organic chemistry techniques such as reaction optimization, purification, and characterization. High-throughput screening is a technique that allows the testing of large libraries of compounds against a target protein in a short amount of time. Medicinal chemistry optimization involves modifying the chemical structure of a compound to improve its potency, selectivity, pharmacokinetics, and other properties [4,5].

Conclusion

The optimization process typically involves a balance between the potency and selectivity of a compound. Potency refers to the ability of a compound to bind to the target protein with high affinity and to induce a pharmacological effect. Selectivity refers to the ability of a compound to bind to the target protein with high specificity and to avoid binding to other proteins or pathways that could cause unwanted side effects. Medicinal chemists use various strategies to improve the potency and selectivity of a compound, such as structure-activity relationship analysis, fragment-based drug design, and multi-target drug design. SAR analysis is a powerful tool for understanding the relationship between the chemical structure of a compound and its biological activity. This analysis involves systematically modifying the chemical structure of a compound and evaluating its potency and selectivity. The data generated from these experiments can be used to develop SAR models that predict the activity of new compounds based on their chemical structure. Fragment-based drug design is a strategy that involves the identification of small fragments that bind to a target protein and the assembly of these fragments into a larger molecule that has high potency and selectivity. This strategy is particularly useful for targeting proteins that are difficult to drug because of their size or complexity. Multi-target drug design is a strategy that involves the simultaneous targeting of multiple proteins or pathways that are implicated in a disease.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Hemlata, Shruti Gupta and Kiran Kumar Tejavath. "ROS-mediated apoptosis induced by BSA nanospheres encapsulated with fruit extract of cucumis prophetarum in various human cancer cell lines." ACS Omega 6 (2021): 10383-10395.

Google Scholar, Crossref, Indexed at

2. Chodari, Leila, Mutlu Dilsiz Aytemir, Parviz Vahedi and Mahdieh Alipour, et al. "Targeting mitochondrial biogenesis with polyphenol compounds." Oxid Med Cell Longev 2021 (2021).

Google Scholar, Crossref, Indexed at

3. Žigrayová, Dominika, Veronika Mikušová and Peter Mikuš. "Advances in antiviral delivery systems and chitosan-based polymeric and nanoparticulate antivirals and antiviral carriers." Viruses 15 (2023): 647.

Google Scholar, Crossref, Indexed at

4. Vincent, Romain, Svetlana Klyatskaya, Mario Ruben and Wolfgang Wernsdorfer, et al. "Electronic read-out of a single nuclear spin using a molecular spin transistor." Nature 488 (2012): 357-360.

Google Scholar, Crossref, Indexed at

5. Thiele, Stefan, Franck Balestro, Rafik Ballou and Svetlana Klyatskaya, et al. "Electrically driven nuclear spin resonance in single-molecule magnets." sci 344 (2014): 1135-1138.

Google Scholar, Crossref, Indexed at